A Study of Experimental FT-2102 in Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome (types of blood system cancer)
This study will evaluate the safety, efficacy, PK, and PD of FT-2102 as a single agent or in combination with azacitidine or cytarabine.
- for people ages 18 years and up (full criteria)
- at UC Davis UCLA
- study startedestimated completion
Acute Myeloid Leukemia, Acute Myelogenous Leukemia, Myelodysplastic Syndrome, AML, MDS, IDH1, IDH, Leukemia, Myeloid Leukemia, Leukemia, Myeloid, Acute, Preleukemia, Myelodysplastic Syndromes, Cytarabine, Azacitidine, FT-2102 (olutasidenib), PH1 Esc. and Exp. FT-2102 (olutasidenib)+Azacitidine, PH1 Esc. and Exp. FT-2102 (olutasidenib)+Cytarabine
- in progress, not accepting new patients
- Start Date
- Completion Date
- Forma Therapeutics, Inc.
- Phase 1/2 research study
- Study Type
- About 336 people participating
- Last Updated